Találati lista | Tudóstér

001-es BibID:	BIBFORM042692
035-os BibID:	PMID:22886098
Első szerző:	Lakatos Péter
Cím:	New considerations on the management of osteoporosis in Central and Eastern Europe (CEE) : summary of the "3rd Summit on Osteoporosis-CEE", November 2009, Budapest, Hungary / Péter Lakatos, Ádám Balogh, Edward Czerwinski, Hans P. Dimai, Didier Hans, Gerold Holzer, Roman S. Lorenc, Vladimir Palicka, Barbara Obermayer-Pietsch, Jan Stepan, István Takács, Heinrich Resch, on behalf of the Members of the "3rd Summit on Osteoporosis-Central and Eastern Europe (CEE)"
Dátum:	2011
ISSN:	1862-3522 1862-3514
Megjegyzések:	In November 2009, the "3rd Summit on Osteoporosis-Central and Eastern Europe (CEE)" was held in Budapest, Hungary. The conference aimed to tackle issues regarding osteoporosis management in CEE identified during the second CEE summit in 2008 and to agree on approaches that allow most efficient and cost-effective diagnosis and therapy of osteoporosis in CEE countries in the future.DISCUSSION:The following topics were covered: past year experience from FRAX? implementation into local diagnostic algorithms; causes of secondary osteoporosis as a FRAX? risk factor; bone turnover markers to estimate bone loss, fracture risk, or monitor therapies; role of quantitative ultrasound in osteoporosis management; compliance and economical aspects of osteoporosis; and osteoporosis and genetics. Consensus and recommendations developed on these topics are summarised in the present progress report.CONCLUSION:Lectures on up-to-date data of topical interest, the distinct regional provenances of the participants, a special focus on practical aspects, intense mutual exchange of individual experiences, strong interest in cross-border cooperations, as well as the readiness to learn from each other considerably contributed to the establishment of these recommendations. The "4th Summit on Osteoporosis-CEE" held in Prague, Czech Republic, in December 2010 will reveal whether these recommendations prove of value when implemented in the clinical routine or whether further improvements are still required.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban külföldön készült közlemény
Megjelenés:	Archives of Osteoporosis. - 6 : 1-2 (2011), p. 1-12. -
További szerzők:	Balogh Ádám (1940-) (szülész-nőgyógyász, endokrinológus szakorvos) Czerwinski, Edward Dimai, Hans P. Hans, Didier Holzer, Gerold Lorenc, Roman Palicka, Vladimir Obermayer-Pietsch, Barbara Stepan, Jan Takács István (szülész-nőgyógyász) Resch, Heinrich 3rd Summit on Osteoporosis-Central and Eastern Europe (CEE)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM042526
035-os BibID:	PMID: 17997711
Első szerző:	Seeman, Ego
Cím:	Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia / Seeman Ego, Devogelaer Jean-Pierre, Lorenc Roman, Spector Timothy, Brixen Kim, Balogh Adam, Stucki Gerold, Reginster Jean-Yves
Dátum:	2008
ISSN:	0884-0431
Megjegyzések:	Many fractures occur in women with moderate fracture risk caused by osteopenia. Strontium ranelate was studied in 1431 postmenopausal women with osteopenia. Vertebral fracture risk reduction of 41-59% was shown depending on the site and fracture status at baseline. This is the first report of antivertebral fracture efficacy in women with vertebral osteopenia.INTRODUCTION:Women with osteoporosis are at high risk for fracture. However, more than one half of all fractures in the community originate from the larger population at more moderate risk of fracture caused by osteopenia. Despite this, evidence for antifracture efficacy in these persons is limited. The aim of this study was to determine whether strontium ranelate, a new drug that reduces fracture risk in women with osteoporosis, is also effective in women with osteopenia.MATERIALS AND METHODS:Data from the Spinal Osteoporosis Therapeutic Intervention study (SOTI; n = 1649) and the TReatment Of Peripheral OSteoporosis (TROPOS; n = 5091) were pooled to evaluate the antivertebral fracture efficacy of strontium ranelate in women with lumbar spine (LS) osteopenia with any BMD value at the femoral neck (FN; N = 1166) and in 265 women with osteopenia at both sites (intention-to-treat analysis). The women were randomized to strontium ranelate 2 g/d orally or placebo for 3 yr.RESULTS:No group differences were present in baseline characteristics that may influence fracture outcome independent of therapy. In women with LS osteopenia, treatment reduced the risk of vertebral fracture by 41% (RR = 0.59; 95% CI, 0.43-0.82), by 59% (RR = 0.41; 95% CI, 0.17-0.99) in the 447 patients with no prevalent fractures, and by 38% (RR = 0.62; 95% CI, 0.44-0.88) in the 719 patients with prevalent fractures. In women with osteopenia at both sites, treatment reduced the risk of fracture by 52% (RR = 0.48; 95% CI, 0.24-0.96).CONCLUSIONS:Strontium ranelate safely reduces the risk of vertebral fractures in women with osteopenia with or without a prevalent fracture.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban osteopenia vertebral fracture risk reduction strontium ranelate
Megjelenés:	Journal of Bone And Mineral Research. - 23 : 3 (2008), p. 433-438. -
További szerzők:	Devogelaer, Jean-Pierre Lorenc, Roman Spector, Timothy Brixen, Kim Balogh Ádám (1940-) (szülész-nőgyógyász, endokrinológus szakorvos) Stucki, Gerold Reginster, Jean-Yves
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: